<DOC>
	<DOCNO>NCT00637442</DOCNO>
	<brief_summary>Examination correlation cerebral bloodflow clinical change treatment Reminyl retard® prediction clinical change measure cerebral bloodflow patient mild moderate Alzheimer 's Disease</brief_summary>
	<brief_title>Continuous Arterial Spin Labeling ( CASL ) MRI Monitoring Prediction Drug Therapy Alzheimers Disease ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Possible Alzheimer 's Disease accord ICD10 NINCDSADRDA Underwritten study consent No treatment acetylcholinesterase inhibitor MiniMentalState Examination : 1225 point Age : 5080 Years Orale contraception woman childbearing age Mental Disorders Other Diseases CNS Severe Illness Contraindication MRIScan Contraindication Galantamin ( Reminyl retard® ) Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>